AGA’s GI Opportunity Fund invests in EndoSound®

AGA’s venture capital fund, the GI Opportunity Fund 1, recently announced it will be investing in EndoSound^®, a company that made waves as the winner of the 2022 AGA Shark Tank competition.

EndoSound is an Oregon-based medical device innovator developing technology that enhances access, reduces costs, and increases the safety of endoscopic ultrasound (EUS) procedures.

The EndoSound Vision System^® (EVS^®) is a disruptive EUS platform. Its attachable transducer and supportive components transform a conventional upper endoscope into a fully functional endoscopic ultrasound device. The cost of existing EUS systems has limited the availability of this crucial modality in the United States and around the world.

By reducing this cost, the EVS will provide physicians with a technological option that can enable care for their patients in a greater number of locations and settings. This brings the potential for enormous benefits to patients, payers, and providers by reducing costs in the healthcare system.

AGA’s venture capital fund, the GI Opportunity Fund 1, recently announced it will be investing in EndoSound^®, a company that made waves as the winner of the 2022 AGA Shark Tank competition.

EndoSound is an Oregon-based medical device innovator developing technology that enhances access, reduces costs, and increases the safety of endoscopic ultrasound (EUS) procedures.

The EndoSound Vision System^® (EVS^®) is a disruptive EUS platform. Its attachable transducer and supportive components transform a conventional upper endoscope into a fully functional endoscopic ultrasound device. The cost of existing EUS systems has limited the availability of this crucial modality in the United States and around the world.

By reducing this cost, the EVS will provide physicians with a technological option that can enable care for their patients in a greater number of locations and settings. This brings the potential for enormous benefits to patients, payers, and providers by reducing costs in the healthcare system.

AGA’s venture capital fund, the GI Opportunity Fund 1, recently announced it will be investing in EndoSound^®, a company that made waves as the winner of the 2022 AGA Shark Tank competition.

EndoSound is an Oregon-based medical device innovator developing technology that enhances access, reduces costs, and increases the safety of endoscopic ultrasound (EUS) procedures.

The EndoSound Vision System^® (EVS^®) is a disruptive EUS platform. Its attachable transducer and supportive components transform a conventional upper endoscope into a fully functional endoscopic ultrasound device. The cost of existing EUS systems has limited the availability of this crucial modality in the United States and around the world.

By reducing this cost, the EVS will provide physicians with a technological option that can enable care for their patients in a greater number of locations and settings. This brings the potential for enormous benefits to patients, payers, and providers by reducing costs in the healthcare system.